Replies to post #4193 on Cytogenix (fka CYGX)

[thalio]

allow me to repeat that last line -

"...making vaccine development [against gram negative bacteria] unrealistic."

Ordinary vaccines target molecules on the surface of bacteria. So what's the problem with that? Again from the same article -

"...O saccharide sidechain also varies considerably within species (>2000 serotypes in Salmonella)."

That means there are more than 2000 variations of a typical molecule you'd want to target with a vaccine just in Salmonella alone.

That's why the article concludes that ordinary vaccines will probably never be developed against a wide variety of gram negative bacteria. There's just no common target on the surface of these guys.

But a molecule that gets inside a bacteria and kills it or stops it from reproducing, a molecule that targets a gene or genes common to an entire class of bacteria...

That's another story. That's OUR story.

Th

[HANUMAN]

THALIO, Have you ever discussed TB with Dr Chen? It would seem to be a likely target for the silencing treatment since it is still rampant in many areas and is resistant to many of the current therapies. Furthermore, the pulmonary form of TB would seemingly be approachable with an aerosole application.
TIA.